Triple Hormone Receptor Agonist Retatrutide for Obesity

What is Retatrutide?
Retatrutide, a new medication created by the pharmaceutical company Eli Lilly, has a major potential for
treating obesity and diabetes. Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist,
or LY3437943, this injectable medication is similar to existing weight loss medications like t
irzepatide and semaglutide but has increased efficacy. When combined with proper diet, r
egular exercise, and lifestyle modifications, retatrutide can help improve weight loss 
outcomes and treat comorbidities related to obesity such as diabetes or hypertension (high blood pressure).
Package: 5mg 10mg  per vial o,10vials per box or  as your needs 
shelf time : 3 years ,keep in the cool place 

How Retatrutide Works?

• Gastric inhibitory polypeptide receptor (GIPR) agonist: As a GIP receptor agonist, retatrutide enhances appetite suppression and prevents fat accumulation, resulting in decreased energy intake and increased energy expenditure.
• Glucagon-like peptide 1 receptor (GLP-1R) agonist: Retatrutide reduces body weight by improving blood sugar levels via enhanced insulin release from the pancreas and reduced release of glucagon (a hormone that increases blood sugar).
• Glucagon receptor (GR) agonist: Retatrutide decreases glucagon release to improve blood sugar levels, decrease food intake, and increase energy expenditure which ultimately results in weight loss.

Products pictures